New York, Jan 30, 2026, 20:47 EST — Market closed
- Johnson & Johnson shares closed almost unchanged on Friday, finishing at $227.25.
- A U.S. judge threw out a fraud lawsuit linked to the company’s talc-related bankruptcy strategy; plaintiffs’ lawyers said they are considering an appeal.
- The company also announced that advisers at the European Medicines Agency supported a broader application of its Akeega prostate-cancer drug.
Johnson & Johnson shares closed nearly flat Friday following Michael Shipp’s dismissal of a fraud lawsuit tied to the company’s failed talc-bankruptcy plan. The stock ended at $227.25, slipping just 0.01% after fluctuating between $225.34 and $228.40 throughout the session. Erik Haas labeled the allegations “wholly meritless,” while plaintiffs’ attorney Patricia Kipnis said she’s reviewing the ruling with clients to consider an appeal. (Reuters)
For investors, the talc docket continues to pose a headline risk, capable of rapidly expanding or shrinking the stock’s “legal discount” despite steady daily trading. Though the fraud case is distinct from the core cancer claims, it’s tangled up in the same battle over the process and venue for resolving those claims.
The company highlighted a regulatory update in Europe that traders often see as incremental but still important when the stock is valued for stability. The Committee for Medicinal Products for Human Use (CHMP) recommended expanding the use of Akeega, a tablet combining niraparib and abiraterone, for a subgroup of metastatic prostate cancer patients with BRCA1/2 mutations. “Pending approval,” Henar Hevia noted, the drug could bring a more targeted approach “earlier in the metastatic pathway.” (Jnj)
The broader market slipped ahead of the weekend. The S&P 500 dropped 0.43%, and the Dow lost 0.36%. Large-cap pharma stocks showed a mixed picture — Pfizer climbed 1.3%, Eli Lilly and Company rose 1.27%, while Johnson & Johnson slipped slightly. The Health Care Select Sector SPDR ETF gained roughly 0.6%. (MarketWatch)
CHMP, the EMA’s scientific committee, provides advice that frequently shapes the European Commission’s final call. According to the company, the recommendation stems from its Phase 3 AMPLITUDE study, which demonstrated a delay in disease progression—that is, patients had more time before scans indicated cancer worsening—and revealed an early, still-developing signal on overall survival.
On the legal front, the dismissed fraud case took aim at the company’s “Texas two-step” maneuver—shifting liabilities into a new entity before filing for bankruptcy—a strategy courts have dismissed in the talc litigation. Johnson & Johnson maintains its talc products are safe and asbestos-free and has ceased selling talc-based baby powder.
One risk for bulls: this week’s dismissal doesn’t erase the underlying talc exposure, and an appeal could keep court headlines coming. On the drug front, a positive panel opinion isn’t a final label—regulators might still tighten the language or demand more on safety and usage.
U.S. markets kick back into gear Monday, Feb. 2, as investors eye the upcoming court filing in the talc lawsuit and await developments on the European review. The next key date for the stock is the Feb. 24 ex-dividend day, with a $1.30 quarterly dividend scheduled for payout on March 10, according to the company. (Jnj)
